NASDAQ:NDRA - ENDRA Life Sciences Stock Price, News & Analysis

ENDRA Life Sciences trades on the NASDAQ under the ticker symbol "NDRA."

ENDRA Life Sciences Inc (NASDAQ:NDRA) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.03. View ENDRA Life Sciences' Earnings History.

ENDRA Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for ENDRA Life Sciences.

3 brokerages have issued 12-month price objectives for ENDRA Life Sciences' stock. Their forecasts range from $6.00 to $6.00. On average, they expect ENDRA Life Sciences' share price to reach $6.00 in the next year. This suggests a possible upside of 287.1% from the stock's current price. View Analyst Price Targets for ENDRA Life Sciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ENDRA Life Sciences.

News headlines about NDRA stock have been trending positive recently, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ENDRA Life Sciences earned a news impact score of 2.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for ENDRA Life Sciences.

ENDRA Life Sciences saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 897,700 shares, an increase of 16.8% from the June 30th total of 768,300 shares. Based on an average trading volume of 132,800 shares, the days-to-cover ratio is currently 6.8 days. Currently, 12.5% of the company's shares are sold short. View ENDRA Life Sciences' Current Options Chain.

Some companies that are related to ENDRA Life Sciences include IRIDEX (IRIX), Precision Optics (PEYE), Digirad (DRAD), Nexeon Medsystems (NXNN), CHF Solutions (CHFS), Non-Invasive Monitoring Systems (NIMU), Aradigm (ARDM), Viveve Medical (VIVE), Vaso (VASO), Reshape Lifesciences (RSLS), Escalon Medical (ESMC), SpectraScience (SCIE), Trimedyne (TMED), Guided Therapeutics (GTHP) and Magna-Lab (MAGAA).

Based on aggregate information from My MarketBeat watchlists, some companies that other ENDRA Life Sciences investors own include Vericel (VCEL), Amarin (AMRN), Aptose Biosciences (APTO), Seanergy Maritime (SHIP), Achieve Life Sciences (ACHV), AcelRx Pharmaceuticals (ACRX), Adverum Biotechnologies (ADVM), Atomera (ATOM), Aurinia Pharmaceuticals (AUPH) and AzurRx BioPharma (AZRX).

(NDRA) raised $10 million in an IPO on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities acted as the underwriters for the IPO.

ENDRA Life Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include ICM Asset Management Inc. WA (10.50%) and Vanguard Group Inc. (3.17%). Company insiders that own ENDRA Life Sciences stock include Longboard Capital Advisors, Ll, Michael Harsh and Michael Milos Thornton. View Institutional Ownership Trends for ENDRA Life Sciences.

NDRA stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for ENDRA Life Sciences.

NDRA stock was acquired by a variety of institutional investors in the last quarter, including ICM Asset Management Inc. WA. Company insiders that have bought ENDRA Life Sciences stock in the last two years include Michael Harsh and Michael Milos Thornton. View Insider Buying and Selling for ENDRA Life Sciences.

Shares of NDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NDRA stock can currently be purchased for approximately $1.55.

ENDRA Life Sciences has a market capitalization of $10.28 million and generates $10,000.00 in revenue each year. The company earns $-9,800,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. ENDRA Life Sciences employs 11 workers across the globe.View Additional Information About ENDRA Life Sciences.

The official website for ENDRA Life Sciences is http://www.endrainc.com/.

ENDRA Life Sciences' mailing address is 3600 GREEN COURT SUITE 350, ANN ARBOR MI, 48105. The company can be reached via phone at 734-335-0468 or via email at [email protected]